en · de · es · pt
lab-handbook.peptides6908.com › Info › Mechanism And Research Context — Evidence Review

Mechanism And Research Context — Evidence Review

By Editorial Desk · published 2025-07-23 · last reviewed 2025-08-14 · Info

LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-08-14. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Research Context

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Identity and Pharmacological Classification

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Cardarine at a glance

PropertyValueNotes
SolubilitySoluble in dimethyl sulfoxide and some organic solvents; practically insoluble in waterSolvent choice affects laboratory handling
Typical storage-20 °C, desiccated, protected from lightCommon condition for research samples
Analytical methodLiquid chromatography–tandem mass spectrometry (LC-MS/MS)Used for identification and quantification in biological or product samples
Common synonymsGW501516, GW-501516, GSK-516, EndurobolNames found in research and anti-doping literature
Regulatory statusUnapproved therapeutic; prohibited in competitive sportStatus can vary by country and context

Detection, Regulation, and Quality Context

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Related pages on this site

Mechanism and Detection Methods

GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.

Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.

Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.

Identity and Pharmacological Mechanism

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.

Regulation and Analytical Detection

Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.

Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.

Background from the literature

Nichols of Purdue University in West Lafayette, Indiana; Kevin Warwick of Reading University, had a microchip implanted in his right arm in August 1998 by George Boulos. A Canadian production, and shown originally on the Canadian science series The Nature of Things on Tuesday 22 January 2002, directed by Mark Halliley, made by Diverse Productions

EPRS1 acts, in human cells, as a proviral factor in mammarenaviruses infection, including LCMV, JUNV, and LASV, and its inhibition using halofuginon compound, a prolyl domain inhibitor, completely abolishes the viral infection by interrupting viral assembly and budding. A diet rich in proline was linked to an increased risk of depression in humans in a study from 2022 that was tested on a limited pre-clinical trial on humans and primarily in other organisms. Results were significant in the other organisms.

=== Cancer === Higher vitamin C intake appears to reduce the risk for lung cancer. There is no evidence that vitamin C supplementation reduces the risk of prostate cancer, colorectal cancer or breast cancer.

=== Secondary glaucoma === Secondary glaucoma (H40.3-H40.6) encompasses numerous subtypes: inflammatory glaucoma (all types of uveitis, Fuchs heterochromic iridocyclitis); phacogenic glaucoma (angle-closure with mature cataract, phacoanaphylactic glaucoma from lens capsule rupture, phacolytic glaucoma, lens subluxation); glaucoma secondary to intraocular hemorrhage (hyphema, hemolytic/erythroclastic glaucoma); traumatic glaucoma (angle recession glaucoma); postsurgical glaucoma (aphakic pupillary block, ciliary block); neovascular glaucoma; drug-induced glaucoma (corticosteroid-induced, alpha-chymotrypsin); and glaucoma of miscellaneous origin (associated with intraocular tumors, retinal detachments, severe chemical burns, essential iris atrophy, or toxic glaucoma). Neovascular glaucoma, an uncommon type of glaucoma, is difficult or nearly impossible to treat, and is often caused by proliferative diabetic retinopathy (PDR) or central retinal vein occlusion (CRVO). It may also be triggered by other conditions that result in ischemia of the retina or ciliary body. Individuals with poor blood flow to the eye are highly at risk for this condition. Neovascular glaucoma results when new, abnormal vessels begin developing in the angle of the eye that begin blocking the drainage. People with such a condition begin to rapidly lose their eyesight. Sometimes, the disease appears very rapidly, especially after cataract surgery procedures. Toxic glaucoma is open-angle glaucoma with an unexplained significant rise of intraocular pressure following an unknown pathogenesis.

Sources: en.wikipedia.org

Reference notes

Critics such as Noam Chomsky argue continuing research into symbolic AI will still be necessary to attain general intelligence, in part because sub-symbolic AI is a move away from explainable AI: it can be difficult or impossible to understand why a modern statistical AI program made a particular decision. The emerging field of neuro-symbolic artificial intelligence attempts to bridge the two approaches.

Bryant, Chad (2009). Prague in Black Nazi Rule and Czech Nationalism. Harvard University Press: Cambridge. ISBN 978-0-674-26166-2. Gruner, Wolf (2015). "Protectorate of Bohemia and Moravia". The Greater German Reich and the Jews: Nazi Persecution Policies in the Annexed Territories 1935–1945. War and Genocide. Berghahn Books. pp. 99–135. ISBN 978-1-78238-444-1. Mahoney, William (2011), The History of the Czech Republic and Slovakia, Santa Barbara: Greenwood Publishing Group, ISBN 978-0-313-36305-4 Miller, Daniel (2005). "The Czech Republic". In Richard C. Frucht (ed.). Eastern Europe An Introduction to the People, Lands, and Culture. Santa Monica: ABC-CLIO. pp. 203–283. ISBN 978-1-57607-800-6. Murray, Williamson (1984). The Change in the European Balance of Power, 1938–1940. Princeton: Princeton University Press. Overy, Richard (1999). "Germany and the Munich Crisis: A Multilated Victory?". In Igor Lukes & Erik Goldstein (ed.). The Munich Crisis, 1938, Prelude to World War II. London: Frank Cass. pp. 191–215. ISBN 0-7146-8056-7. Rothwell, Victor (2001). The Origins of the Second World War. Manchester: Manchester University Press. ISBN 978-0-7190-5958-2. Tooze, Adam (2006). The Wages of Destruction The Making and Breaking of the Nazi Economy. London: Allan Lane. ISBN 978-0-7139-9566-4.

== Etymology == The word poison was first recorded in English around the year 1200, meaning "a deadly potion or substance". It derives from the Old French poison or puison (12th century; Modern French: poison), originally meaning "a drink", particularly a medicinal one. By the 14th century, the term had come to signify "a (magic) potion" or "poisonous drink". These uses trace back to the Latin word potionem (nominative: potio), meaning "a drinking" or "a drink", and more specifically "a poisonous drink", as seen in the writings of Cicero. The Latin root comes from the verb potare, meaning "to drink". The use of poison as an adjective in the form poisonous dates back to the 1520s. The practice of using poison in combination with plant names began in the 18th century. For example, the term poison oak was first recorded in 1743, and poison ivy appeared in usage by 1784. The expression poison gas was first used during World War I in 1915.

Sources: en.wikipedia.org

Frequently asked questions

How does cardarine work in the body?

It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.

Is cardarine a steroid?

No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.

What do human studies show?

Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.

What is cardarine also known as?

Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.

Network